A5091066647- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
- Renal cell carcinoma treatment
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Endometrial and Cervical Cancer Treatments
- Immune cells in cancer
- Genetic Associations and Epidemiology
- vaccines and immunoinformatics approaches
- Intraperitoneal and Appendiceal Malignancies
- Virus-based gene therapy research
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Epigenetics and DNA Methylation
- Renal and related cancers
- CRISPR and Genetic Engineering
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- RNA Interference and Gene Delivery
- Prostate Cancer Treatment and Research
- Immunodeficiency and Autoimmune Disorders
Roswell Park Comprehensive Cancer Center
2016-2025
NRG Oncology
2015-2024
Gynecologic Oncology Group
2011-2024
Alabama College of Osteopathic Medicine
2024
Columbia University
2024
Cancer Research And Biostatistics
2012-2023
Versiti Blood Center of Wisconsin
2023
Pontifícia Universidade Católica do Rio Grande do Sul
2022
Memorial Hospital
2022
Texas A&M University
2022
NY-ESO-1 is a “cancer-testis” antigen frequently expressed in epithelial ovarian cancer (EOC) and among the most immunogenic tumor antigens defined to date. In an effort understand vivo tolerance mechanisms, we assessed phenotype function of NY-ESO-1–specific CD8 + T cells derived from peripheral blood lymphocytes (PBLs), tumor-infiltrating (TILs), tumor-associated (TALs) EOC patients with NY-ESO-1-expressing tumors, or without humoral immunity NY-ESO-1. Whereas were readily detectable ex...
Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and skin cancers, has been shown preliminary clinical activity in this population.
Myeloid-derived suppressor cells (MDSCs) comprise immature myeloid populations produced in diverse pathologies, including neoplasia. Because MDSCs can impair antitumor immunity, these have emerged as a significant barrier to cancer therapy. Although much research has focused on how promote tumor progression, it remains unclear develop and why the MDSC response is heavily granulocytic. Given that are manifestation of aberrant myelopoiesis, we hypothesized arise from perturbations regulation...
To evaluate the addition of humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC).This multicenter placebo-controlled double-blind randomized phase trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with untreated International Federation Gynecology Obstetrics (FIGO) OC who either had undergone primary cytoreductive surgery macroscopic residual...
Abstract The extent to which T-cell–mediated immune surveillance is impaired in human cancer remains a question of major importance, given its potential impact on the development generalized treatments advanced disease where highest degree heterogeneity exists. Here, we report first global analysis dysfunction patients with hepatocellular carcinoma (HCC). Using multi-parameter fluorescence-activated cell sorting analysis, quantified cumulative frequency regulatory T cells (Treg), exhausted...
Myeloid-derived suppressor cells (MDSC) are induced under diverse pathologic conditions, including neoplasia, and suppress innate adaptive immunity. While the mechanisms by which MDSC mediate immunosuppression well-characterized, details on how they develop remain less understood. This is complicated further fact that comprise multiple myeloid cell types, namely monocytes granulocytes, reflecting stages of differentiation proportion these subpopulations vary among different neoplastic...
To examine the effects of disease burden, complex surgery, and residual (RD) status on progression-free (PFS) overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) or primary peritoneal (PPC) complete surgical resection (R0) < 1 cm RD (MR) after cytoreduction.
A hallmark of human cancer is global DNA hypomethylation (GDHO), but the mechanisms accounting for this defect and its pathological consequences have not been investigated in epithelial ovarian (EOC). In EOC, GDHO was associated with advanced disease reduced overall disease-free survival. (+) EOC tumors displayed a proliferative gene expression signature, including FOXM1 CCNE1 overexpression. Furthermore, these enriched within genomic blocks (hypomethylated blocks) that overlapped...
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed activity two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS AND METHODS NRG-GY004 an open-label, randomized, phase III trial conducted in United States and Canada. Eligible patients had high-grade serous endometrioid cancer. Patients were randomly assigned 1:1:1...
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune responses that will improve outcome. To test whether a diversified prime boost regimen targeting NY-ESO-1 result benefit, we conducted two parallel phase II of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1), followed by booster vaccinations with fowlpox-NY-ESO-1 (rF-NY-ESO-1) 25 melanoma 22 epithelial ovarian (EOC)...
Abstract The cancer–testis/cancer germline antigen, NY-ESO-1, is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression barrier to efficacy. As NY-ESO-1 regulated by DNA methylation, we hypothesized that methyltransferase inhibitors may augment therapy. In agreement, global hypomethylation EOC was associated with the presence of circulating antibodies NY-ESO-1. Preclinical studies using cell lines showed decitabine treatment enhanced both and NY-ESO-1–specific...
Rationale: Previous studies from our laboratory have shown that peripheral blood mononuclear cells (PBMCs) patients with chronic obstructive pulmonary disease (COPD) prone to exacerbations nontypeable Haemophilus influenzae impaired responses lipoprotein P6. We hypothesized an underlying immunosuppressive network could be responsible for the defective antibacterial immunity observed in these patients. evaluated T regulatory (Tregs), myeloid-derived suppressor (MDSC), and exhausted effector...
Fixed-dose rate gemcitabine plus docetaxel achieves objective response in 35% of patients with uterine leiomyosarcoma (uLMS). This study aimed to determine whether the addition bevacizumab gemcitabine-docetaxel increases progression-free survival (PFS) uLMS.In this phase III, double-blind, placebo-controlled trial, chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned or placebo. PFS, overall (OS), and rates (ORRs) compared superiority. Target accrual was 130 detect an...
In patients with chronic lymphocytic leukemia (CLL), treatment lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this remains unknown.Forty-five CLL who were treated in phase 2 trial evaluated for the features, intensity, and duration TFR. Correlation was made cellular microenvironment. Steroids prophylaxis TFR not given to Group A (n = 29) whereas B 16) received low-dose prednisone as well slow dose...
Abstract Purpose: Treatment options are limited for patients with high-risk myelodysplastic syndrome (MDS). The azanucleosides, azacitidine and decitabine, first-line therapy MDS that induce promoter demethylation gene expression of the highly immunogenic tumor antigen NY-ESO-1. We demonstrated acute myeloid leukemia (AML) receiving decitabine exhibit induction NY-ESO-1 in circulating blasts. hypothesized vaccinating against would capitalize upon induced malignant cells to provoke an...
Purpose: While stereotactic body radiotherapy (SBRT) can reduce tumor volumes in patients with metastatic renal cell carcinoma (mRCC), little is known regarding the immunomodulatory effects of high-dose radiation microenvironment. The main objectives this pilot study were to assess safety and feasibility nephrectomy following SBRT treatment mRCC analyze immunological impact radiation.Experimental Design: Human RCC lines irradiated evaluated for immunomodulation. In a single-arm study,...
Abstract Alterations in myelopoiesis are common across various tumor types, resulting immature populations termed myeloid-derived suppressor cells (MDSCs). MDSC burden correlates with poorer clinical outcomes, credited to their ability suppress antitumor immunity. MDSCs consist of two major subsets, monocytic and polymorphonuclear (PMN). Intriguingly, the latter subset predominates many patients models, although mechanisms favoring PMN-MDSC responses remain poorly understood. Ordinarily,...
Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, addition to its properties, sorafenib may beneficially reduce the extent of immunosuppressive network HCC patients. To test this hypothesis, examined whether alterations burden patients correlated with clinical outcome.In before after treatment, blood samples collected from 19 advanced HCC, frequency PD-1+ T cells, Tregs,...